## SEC Form 4

 $\square$ 

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB APPROVAL OMB Number: 3235-0287

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person*   Kramer Robert   (Last) (First) (Middle)   2273 RESEARCH BLVD, SUITE 400			2. Issuer Name <b>and</b> Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]	(Check	tionship of Reporting Perso all applicable) Director Officer (give title	n(s) to Issuer 10% Owner Other (specify
			3. Date of Earliest Transaction (Month/Day/Year) 05/29/2007	Х	below) EVP Manufacturii	below)
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing ( Form filed by One Report Form filed by More than ( Person	ting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code V Amoun		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	05/29/2007		М		14,190	A	<b>\$0.1</b>	14,190	D	
Common Stock	05/29/2007		S		14,190	D	\$10.72(1)	0	D	
Common Stock	05/30/2007		М		14,190	A	<b>\$0.1</b>	14,190	D	
Common Stock	05/30/2007		S		14,190	D	<b>\$10.16</b> <sup>(2)</sup>	0	D	

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Seci Acq (A) ( Disp of (E	umber vative urities uired or oosed D) (Instr. and 5)	Expiration Date (Month/Day/Year)		Expiration Date		ate of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$0.1	05/29/2007		М			14,190	06/30/2004	06/30/2007	Common Stock	14,190	\$0	453,338	D			
Employee Stock Option (right to buy)	\$0.1	05/30/2007		М			14,190	06/30/2004	06/30/2007	Common Stock	14,190	\$0	439,148	D			

#### Explanation of Responses:

1. Reflects the average sales price of shares sold by Merrill Lynch on such date in its administration of Rule 10b5-1 trading plans for Emergent BioSolutions Inc. common stock. These shares were sold at prices ranging from \$10.41 to \$11.29 per share.

2. Reflects the average sales price of shares sold by Merrill Lynch on such date in its administration of Rule 10b5-1 trading plans for Emergent BioSolutions Inc. common stock. These shares were sold at prices ranging from \$10.13 to \$10.40 per share.

/s/Daniel Abdun-Nabi,	
attorney-in-fact	

05/31/2007

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.